A lawyer representing a slate of patients allegedly harmed by experimental treatment with Medtronic’s Infuse bone graft says there may be “hundreds and hundreds” more patient complaints in the wings.
There may be “hundreds and hundreds” of patients with complaints against medical device giant Medtronic (NYSE:MDT) and a spinal surgeon accused of performing experimental surgeries without informed consent.
It’s the latest development in the dramatic saga of Medtronic’s controversial Infuse bone morphogenetic protein, which was at the center of a Justice Dept. criminal investigation that closed last year without evidence of wrongdoing.
